Tectonic Therapeutics TECX EBITDA

EBITDA at other companies

ALN

Alnylam PharmaceuticalsALNY

$245.34M+10,980%

Septerna, Inc.SEPN

-$16.41M+42.6%

Gyre Therapeutics, Inc.GYRE

-$12.88M-946%

RegenxbioRGNX

$33.02M+156%

Opko HealthOPK

$15.44M+142%

CelcuityCELC

-$50.46M-39.8%

FAQ

What is Tectonic Therapeutics's EBITDA?

Tectonic Therapeutics (TECX) reported EBITDA of -$27M in Q1 2026.

How has Tectonic Therapeutics's EBITDA changed year-over-year?

Tectonic Therapeutics's EBITDA decreased by 50.5% year-over-year, from -$17.94M to -$27M.

What is the long-term trend for Tectonic Therapeutics's EBITDA?

Over 4 years (2021 to 2025), Tectonic Therapeutics's EBITDA has grown at a -8.4% compound annual growth rate (CAGR), from -$117.44M to -$82.66M.

What does EBITDA mean?

Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.